N,N-dimethyl-3-(pyridin-3-yl)prop-2-yn-1-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N,N-dimethyl-3-(pyridin-3-yl)prop-2-yn-1-amine
• 英文别名: Dimethyl[3-(pyridin-3-yl)prop-2-yn-1-yl]amine；N,N-dimethyl-3-pyridin-3-ylprop-2-yn-1-amine
• 化学式: C₁₀H₁₂N₂
• 分子量: 160.219
• InChiKey: OFJZYKKOFXREQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N-dimethyl-3-(pyridin-3-yl)prop-2-yn-1-amine 在 1,2,3,4,5,6,7,8-八硫杂环辛烷 、 potassium dihydrogenphosphate 、 copper(l) chloride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以55%的产率得到5-(pyridin-3-yl)-3H-1,2-dithiole-3-thione
  参考文献：
  名称：

  铜催化苯丙炔胺硫环化合成1,2-二硫-3-硫酮 衍生物的方法

  摘要：

  本发明涉及一种铜催化炔丙胺硫环化合成1,2‑二硫‑3‑硫酮衍生物的方法，以N,N‑二甲基‑3‑苯基丙‑2‑炔‑1‑胺为底物，通过在底物中加入氯化亚铜、溴化亚铜或碘化亚铜作为催化剂，磷酸钾、碳酸氢钠或醋酸钠作为碱，单质硫作为硫源在溶剂中，于100‑120℃下，搅拌反应12小时。本发明使用单质硫作为硫源，具有原料简单易得，反应操作简单、条件相对温和、底物普适性广、产率较高、官能团兼容性良好的优点。

  公开号：

  CN109776489B
• 作为产物：
  描述：

  3-(3-吡啶基)-2-丙炔-1-醇 在 氯化亚砜 作用下， 以 氯仿 、 水 为溶剂， 生成 N,N-dimethyl-3-(pyridin-3-yl)prop-2-yn-1-amine
  参考文献：
  名称：

  Synthesis and binding of 6,7,8,9-tetrahydro-5H-pyrido[3,4-d]azepine and related ring-opened analogs at central nicotinic receptors

  摘要：

  6,7,8,9-Tetrahydro-5H-pyrido[3,4-d]azepine (5a) and its N-7-methyl derivative 5b were synthesized and evaluated as potential nicotinic acetylcholinergic receptor (nAChR) ligands. On the basis that 6,7,8,9-tetrahydro-5H-pyrido[3,4-c]azepine (4a), which binds at nAChRs with low affinity (K-i = 1100 nM), possesses an internitrogen distance (4.6 Angstrom) that may be less than optimal, we designed compound 5a due to its similar shape but longer internitrogen distance (5.5 Angstrom). Compound 5a (K-i = 45 nM) was found to bind with enhanced affinity. However, unlike what is seen with nornicotine/nicotine, N-methylation of 5a reduced affinity (5b; K-i = 268 nM) rather than enhancing it. The results suggest that 5 may interact at nicotine receptors in a manner that is somewhat different from that of nicotine. Ring-opening of the pyrido[3,4-d]azepine ring led to a series of 3-(2-aminoethyl)pyridines 21 that retained the affinity of the cyclic compound. Subsequent modification, including further chain lengthening (e.g. aminopropylpyridines 22) and introduction of unsaturation, ultimately led to the development of a series of 3-(2-aminethoxy)pyridines 27. Simple N-substituted derivatives of 27 were found to bind with K-i values of 20 to 35 nM. Because parallel structural changes in several series of related compounds did not result in parallel shifts in nAChR affinity, it is unlikely that all the investigated compounds bind in a similar fashion at these receptors. Nevertheless, some of these compounds represent novel classes of nAChR ligands. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(99)80051-8

文献信息

• [EN] SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER<br/>[FR] COMPOSES SYNTHETIQUES ET DERIVES DE CEUX-CI EN TANT QUE MODULATEURS DE FUMEE OU D'INGESTION DE NICOTINE ET DU CANCER DU POUMON
  申请人：HUMAN BIOMOLECULAR RES INST

  公开号：WO2005066162A1

  公开（公告）日：2005-07-21

  Disclosed are nicotine-related compounds that selectively inhibit cytochrome P-450 2A6 (CYP2A6), selectively inhibit cytochrome P-450 2A13 (CYP2A13), and/or selectively modulate a nicotinic acetylcholine receptor (nAChR). Also disclosed are pharmaceutical compositions comprising a compound of the invention, as well as methods of using the pharmaceutical compositions for treating or preventing a disease or disorder associated with nicotine-ingestion, or a disease or disorder amenable to treatment by selective modulation of nAChRs.

  本公开了与尼古丁相关的化合物，其选择性地抑制细胞色素P-450 2A6（CYP2A6），选择性地抑制细胞色素P-450 2A13（CYP2A13），和/或选择性地调节尼古丁型乙酰胆碱受体（nAChR）。还公开了包含本发明化合物的药物组合物，以及使用这些药物组合物治疗或预防与尼古丁摄入相关的疾病或紊乱，或者通过选择性调节nAChRs治疗的疾病或紊乱的方法。
• Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
  申请人：Cashman John R.

  公开号：US20080188527A1

  公开（公告）日：2008-08-07

  Disclosed are nicotine-related compounds that selectively inhibit cytochrome P-450 2A6 (CYP2A6), selectively inhibit cytochrome P-450 2A13 (CYP2A13), and/or selectively modulate a nicotinic acetylcholine receptor (nAChR). Also disclosed are pharmaceutical compositions comprising a compound of the invention, as well as methods of using the pharmaceutical compositions for treating or preventing a disease or disorder associated with nicotine-ingestion, or a disease or disorder amenable to treatment by selective modulation of nAChRs.

  本发明涉及选择性抑制细胞色素P-450 2A6（CYP2A6）、选择性抑制细胞色素P-450 2A13（CYP2A13）和/或选择性调节尼古丁乙酰胆碱受体（nAChR）的尼古丁相关化合物。本发明还涉及包含本发明化合物的制药组合物，以及使用该制药组合物治疗或预防与尼古丁摄入相关的疾病或障碍，或可通过选择性调节nAChR进行治疗的疾病或障碍的方法。
• Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
  申请人：Cashman John R.

  公开号：US08609708B2

  公开（公告）日：2013-12-17

  Disclosed are nicotine-related compounds that selectively inhibit cytochrome P-450 2A6 (CYP2A6), selectively inhibit cytochrome P-450 2A13 (CYP2A13), and/or selectively modulate a nicotinic acetylcholine receptor (nAChR). Also disclosed are pharmaceutical compositions comprising a compound of the invention, as well as methods of using the pharmaceutical compositions for treating or preventing a disease or disorder associated with nicotine-ingestion, or a disease or disorder amenable to treatment by selective modulation of nAChRs.

  本发明揭示了一些与尼古丁相关的化合物，它们具有选择性地抑制细胞色素P-450 2A6（CYP2A6），选择性地抑制细胞色素P-450 2A13（CYP2A13），和/或选择性地调节一种尼古丁乙酰胆碱受体（nAChR）。同时，本发明还揭示了包括本发明化合物的制药组合物，以及使用该制药组合物治疗或预防与尼古丁摄入相关的疾病或障碍，或者通过选择性调节nAChRs治疗的疾病或障碍的方法。
• SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER
  申请人：Cashman John R.

  公开号：US20100298345A1

  公开（公告）日：2010-11-25

  Disclosed are nicotine-related compounds that selectively inhibit cytochrome P-450 2A6 (CYP2A6), selectively inhibit cytochrome P-450 2A13 (CYP2A13), and/or selectively modulate a nicotinic acetylcholine receptor (nAChR). Also disclosed are pharmaceutical compositions comprising a compound of the invention, as well as methods of using the pharmaceutical compositions for treating or preventing a disease or disorder associated with nicotine-ingestion, or a disease or disorder amenable to treatment by selective modulation of nAChRs.

  本发明涉及选择性抑制细胞色素P-450 2A6（CYP2A6）的尼古丁相关化合物，选择性抑制细胞色素P-450 2A13（CYP2A13），和/或选择性调节尼古丁乙酰胆碱受体（nAChR）。本发明还涉及包含本发明化合物的制药组合物，以及使用该制药组合物治疗或预防与尼古丁摄入有关的疾病或障碍，或者通过选择性调节nAChRs进行治疗的疾病或障碍的方法。
• Cu/Oxalic Diamide-Catalyzed Coupling of Terminal Alkynes with Aryl Halides
  作者：Ying Chen、Sailuo Li、Lanting Xu、Dawei Ma

  DOI：10.1021/acs.joc.2c02882

  日期：2023.3.3

  6-Dimethylphenyl)-N2-(pyridin-2-ylmethyl)oxalamide (DMPPO) was revealed to be a more effective ligand for copper-catalyzed coupling reaction of (hetero)aryl halides with 1-alkynes than previously reported ones. Only 3 mol % CuCl and DMPPO are required to make the coupling complete at 100 °C (for bromides) and 80 °C (for iodides). Both (hetero)aryl and alkyl substituted 1-alkynes worked well under these conditions

  N 1 -(2,6-二甲基苯基)- N 2 -(吡啶-2-基甲基)草酰胺 (DMPPO) 被发现是铜催化的（杂）芳基卤化物与 1-炔烃偶联反应的更有效配体以前报道过的。仅需 3 mol% CuCl 和 DMPPO 即可在 100 °C（溴化物）和 80 °C（碘化物）下完成偶联。（杂）芳基和烷基取代的 1-炔烃在这些条件下都表现良好，导致内部炔烃的形成具有很大的多样性。